Amgen continues to rule the Top 10 Biopharma rankings, but 2005 saw a couple of players make great strides. Genentech and Gilead continued to post huge gains (+46% each) on the strength of their oncology and HIV drugs, respectively.
Chiron also eked its way back into the billion-dollar ranks after its vaccine-manufacturing disaster in 2004, but it wasn’t enough to help the company stay independent; the company was bought by Novartis and will disappear from this chart next year.
—Gil Y. Roth
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
Top 10 Biopharmaceutical Companies
based on 2005 biopharma revenues
2005 R&D Expenditures